|
|
|
|
| LEADER |
03062nam a22003375i 4500 |
| 001 |
000277408 |
| 005 |
20210412132641.0 |
| 007 |
cr nn 008mamaa |
| 008 |
130607s2011 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781441974150
|
| 024 |
7 |
|
|a 10.1007/978-1-4419-7415-0
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Clinical Trial Simulations :
|b Applications and Trends /
|c edited by Holly H. C. Kimko, Carl C. Peck.
|
| 250 |
|
|
|a 1st ed. 2011.
|
| 260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2011.
|
| 300 |
|
|
|a XVI, 540 p. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a AAPS Advances in the Pharmaceutical Sciences Series,
|v 1
|
| 505 |
0 |
|
|a Clinical Trial Simulation and Quantitative Pharmacology -- Contribution of Modeling and Simulation Studies in the Regulatory Review: A European Regulatory Perspective -- Contribution of Modeling and Simulation in the Regulatory Review and Decision-Making: U.S FDA Perspective -- Decision-Making in Drug Development: Application of a Model Based Framework for Assessing Trial Performance -- Decision-Making in Drug Development: Application of a Clinical Utility Index -- Adaptive Trial Designs -- Keys of Collaboration to Enhance Efficiency and Impact of Modeling and Simulation -- Leveraging Pharmacometrics in Early Phase Anti-Inflamatory Dug Development -- The Application of Drug-Disease Models in the Development of Anti-Hyperglycemic Agents -- Modeling and Simulation in the Development of Cardiovascular Agents -- Viral Dynamic Modeling and Simulations in HIV and Hepatitis C -- A Model-Based PK/PD Antimicrobial Chemotherapy Drug Development Platform to Simultaneously Combat Infectious Diseases and Drug Resistance -- PKPD and Disease Modeling: Concepts and Applications to Oncology -- Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Erythropoietic Stimulating Agents -- Model Based Development of an Agent for the Treatment of Generalized Anxiety Disorder -- Balancing Efficacy and Safety in the Clinical Development of an Atypical Antipsychotic, Paliperidone Extended-Release -- Application of Modeling and Simulation in the Development of Protein Drugs -- Modeling and Simulation in Pediatric Research and Development -- Disease Progression Analysis: Towards Mechanism-Based Models -- Using a Systems Biology Approach to Explore Hypotheses Underlying Clinical Diversity of the Renin Angiotensin System and the Response to Antihypertensive Therapies -- Recent Developments in Physiologically Based Pharmacokinetic Modeling -- Covariate Distribution Models in Simulation.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Biochemistry.
|
| 650 |
1 |
4 |
|a Biomedicine, general.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Biochemistry, general.
|
| 700 |
1 |
|
|a Kimko, Holly H. C.
|e editor.
|
| 700 |
1 |
|
|a Peck, Carl C.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|